FTC insists generics ANI and Novitium divest IP before merger

The Federal Trade Commission (FTC) has stipulated that generic drug marketers ANI Pharmaceuticals, and Novitium Pharma must divest IP rights to Prasco ahead of their $210 million merger.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

AstraZeneca partners with Chinese firm ahead of next obesity race

5 February 2026 The British-Swedish pharma giant pays $1.2 billion upfront for access to next-generation weight-loss treatment as China patent cliff changes the market.

Europe

INTA: ‘Davos of IP’ will take London meeting to a ‘different level’

5 February 2026 Excitement is mounting for the world’s largest IP gathering, which will see the industry’s elites travelling to the UK in the spring, reveals the association’s CEO.

Careers

Nine-partner litigation team leaves Winston & Strawn

5 February 2026 The trial group, which brings “exceptional litigation talent”, joins larger firm in Texas and Washington, DC, coinciding with the announcement of the Winston Taylor merger.

More features

AstraZeneca partners with Chinese firm ahead of next obesity race

INTA: ‘Davos of IP’ will take London meeting to a ‘different level’

Nine-partner litigation team leaves Winston & Strawn

Squire Patton Boggs brings in tech and data expert as Ireland practice lead

LSPN Awards USA returns for second year—with new categories

Drowning in EU regulations? Five tips for surviving the deluge of new rules

Moderna VP and regulatory expert moves to private practice

Crowell adds tech partner with in-house and private practice expertise

FTC insists generics ANI and Novitium divest IP before merger

More on this story

Editor's picks

Editor's picks

More features